Database for pancreatic cancer patients
Establishment of a Monocentric and Prospective Clinico-biological Database in Patients With Pancreatic Adenocarcinoma
This study is creating a detailed database to help researchers learn more about pancreatic cancer and how different cells in the tumor affect its growth and treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy, erlotinib |
| Locations | 1 site (Montpellier, Occ) |
| Trial ID | NCT04136132 on ClinicalTrials.gov |
What this trial studies
This study aims to create a comprehensive clinical-biological database for patients diagnosed with pancreatic adenocarcinoma. It focuses on understanding the tumor's microenvironment and the various cell types involved in its progression. By utilizing advanced technologies like CyTOF, researchers will analyze the stroma of the tumor, which constitutes a significant portion of its mass, to better characterize the disease and its treatment responses. The goal is to enhance the understanding of pancreatic cancer and potentially improve therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are being treated for pancreatic adenocarcinoma and are eligible for surgery or chemotherapy.
Not a fit: Patients who are not affiliated with a social security scheme or those who cannot maintain regular follow-up due to various reasons may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options and outcomes for patients with pancreatic cancer.
How similar studies have performed: While there have been studies focusing on pancreatic cancer, this approach of creating a detailed clinical-biological database is relatively novel and may provide new insights into the disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over the age of 18; * Patient managed for pancreatic adenocarcinoma; * Patient eligible for at least one (or more) surgery (s) and chemotherapy; * Patient giving informed consent Exclusion Criteria: * Patient not affiliated to a social security scheme; * Pregnant and / or nursing patient; * Patient under guardianship, curatorship or safeguard of justice; * Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons.
Where this trial is running
Montpellier, Occ
- Institut Régional du Cancer de Montpellier — Montpellier, Occ, France (Recruiting)
Study contacts
- Study coordinator: Aurore MOUSSION
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: 0467613102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.